• Axsome Therapeutics recently obtained exclusive global rights from Takeda Pharmaceutical to balipodect (TAK-063), a selective PDE10A inhibitor for central nervous system disorders including schizophrenia and Tourette syndrome, and plans Phase 3 trial-enabling work during 2026.
• This deal broadens Axsome’s late-stage neuropsychiatry pipeline with a clinically tested asset that has shown a favorable safety and tolerability profile, potentially reshaping its long-term portfolio mix.
• We’ll now examine how adding balipodect, a late-stage schizophrenia candidate, could influence Axsome’s broader investment narrative and risk profile.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Axsome Therapeutics Investment Narrative Recap

To own Axsome, you need to believe its commercial CNS portfolio can eventually offset today’s net losses and concentrated revenue base in Auvelity and Sunosi. The balipodect deal adds another late stage asset but does not change the near term focus on execution for existing products, where payer pressure, high gross to net discounts, and elevated SG&A remain the most immediate risks.

The most relevant recent announcement alongside balipodect is Axsome’s full year 2025 update, with about US$638.5 million in revenue and continued net losses. Those results highlight the core tension here: management is adding late stage programs like balipodect while already funding multiple Phase 3 trials and launches, which could extend the period of cash burn and keep dilution and liquidity risk on the table.

Yet behind the expanding pipeline, one key issue investors should be aware of is the persistent net losses and finite cash runway...

Axsome Therapeutics' narrative projects $2.1 billion revenue and $714.0 million earnings by 2029. This requires 47.8% yearly revenue growth and about an $897 million earnings increase from -$183.2 million today.

Uncover how Axsome Therapeutics' forecasts yield a $222.47 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Before this Takeda deal, the most cautious analysts were still assuming Axsome could reach about US$1.5 billion in revenue and US$433.1 million in earnings by 2029, which is far more optimistic than a thesis focused on rising AUVELITY and SUNOSI discounts and heavier Phase 3 spending alone, so you should expect opinions on Axsome’s risk reward after balipodect to vary just as widely.

Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.